91 related articles for article (PubMed ID: 30138434)
1. Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
Isermann T; Schneider KL; Wegwitz F; De Oliveira T; Conradi LC; Volk V; Feuerhake F; Papke B; Stintzing S; Mundt B; Kühnel F; Moll UM; Schulz-Heddergott R
bioRxiv; 2024 Feb; ():. PubMed ID: 38464125
[TBL] [Abstract][Full Text] [Related]
2. Heat shock factor 1 inhibition enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model.
Viana PHL; Schvarcz CA; Danics LO; Besztercei B; Aloss K; Bokhari SMZ; Giunashvili N; Bócsi D; Koós Z; Benyó Z; Hamar P
Sci Rep; 2024 Apr; 14(1):8241. PubMed ID: 38589452
[TBL] [Abstract][Full Text] [Related]
3. Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review.
Zarguan I; Ghoul S; Belayachi L; Benjouad A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791506
[TBL] [Abstract][Full Text] [Related]
4. The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Moreno R; Banerjee S; Jackson AW; Quinn J; Baillie G; Dixon JE; Dinkova-Kostova AT; Edwards J; de la Vega L
Cell Death Differ; 2021 May; 28(5):1563-1578. PubMed ID: 33268814
[TBL] [Abstract][Full Text] [Related]
5. Tuning Hsf1 levels drives distinct fungal morphogenetic programs with depletion impairing Hsp90 function and overexpression expanding the target space.
Veri AO; Miao Z; Shapiro RS; Tebbji F; O'Meara TR; Kim SH; Colazo J; Tan K; Vyas VK; Whiteway M; Robbins N; Wong KH; Cowen LE
PLoS Genet; 2018 Mar; 14(3):e1007270. PubMed ID: 29590106
[TBL] [Abstract][Full Text] [Related]
6. Decrypting the chaperone code.
Truman AW; Bourboulia D; Mollapour M
J Biol Chem; 2021; 296():100293. PubMed ID: 33837727
[No Abstract] [Full Text] [Related]
7. Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy.
Fierro-Monti I; Echeverria P; Racle J; Hernandez C; Picard D; Quadroni M
PLoS One; 2013; 8(11):e80425. PubMed ID: 24312219
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibition leads to an increase in surface expression of multiple immunological receptors in cancer cells.
Wickenberg M; Mercier R; Yap M; Walker J; Baker K; LaPointe P
Front Mol Biosci; 2024; 11():1334876. PubMed ID: 38645275
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional complexity of HSP90 in cellular homeostasis and disease.
Chiosis G; Digwal CS; Trepel JB; Neckers L
Nat Rev Mol Cell Biol; 2023 Nov; 24(11):797-815. PubMed ID: 37524848
[TBL] [Abstract][Full Text] [Related]
10. HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets/Tools for Therapy.
Kabakov AE; Gabai VL
Cells; 2021 Dec; 10(12):. PubMed ID: 34943954
[TBL] [Abstract][Full Text] [Related]
11. With or without You: Co-Chaperones Mediate Health and Disease by Modifying Chaperone Function and Protein Triage.
Altinok S; Sanchez-Hodge R; Stewart M; Smith K; Schisler JC
Cells; 2021 Nov; 10(11):. PubMed ID: 34831344
[TBL] [Abstract][Full Text] [Related]
12. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.
Anwar MM; Shalaby M; Embaby AM; Saeed H; Agwa MM; Hussein A
Sci Rep; 2020 Sep; 10(1):14706. PubMed ID: 32895397
[TBL] [Abstract][Full Text] [Related]
13. Proteotoxic Stress and Cell Death in Cancer Cells.
Brancolini C; Iuliano L
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32842524
[TBL] [Abstract][Full Text] [Related]
14. The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity.
Echeverria PC; Bhattacharya K; Joshi A; Wang T; Picard D
PLoS One; 2019; 14(2):e0208287. PubMed ID: 30726209
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition.
Pastorek M; Muller P; Coates PJ; Vojtesek B
PLoS One; 2018; 13(8):e0202758. PubMed ID: 30138434
[TBL] [Abstract][Full Text] [Related]
16. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation.
Kijima T; Prince TL; Tigue ML; Yim KH; Schwartz H; Beebe K; Lee S; Budzynski MA; Williams H; Trepel JB; Sistonen L; Calderwood S; Neckers L
Sci Rep; 2018 May; 8(1):6976. PubMed ID: 29725069
[TBL] [Abstract][Full Text] [Related]
18. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
Yallowitz A; Ghaleb A; Garcia L; Alexandrova EM; Marchenko N
Cell Death Dis; 2018 May; 9(6):621. PubMed ID: 29799521
[TBL] [Abstract][Full Text] [Related]
19. The Role of HSF1 Protein in Malignant Transformation.
Šimončík O; Pastorek M; Vojtěšek B; Müller P
Klin Onkol; 2018; 31(Suppl 2):55-62. PubMed ID: 31023025
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
